Answer
For patients with hepatic impairment taking icosapent ethyl, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations should be monitored as clinically indicated before treatment starts and at appropriate intervals during treatment.
Sources for this answer
- VazkepaRecordati Pharmaceuticals Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 4Document updated
Sources checked